Iovance Biotherapeutics, Inc. Earnings

Iovance Biotherapeutics, Inc.’s revenue jumped 92.73% since last year same period to $59.95Mn in the Q2 2025. On a quarterly growth basis, Iovance Biotherapeutics, Inc. has generated 21.55% jump in its revenue since last 3-months.

Iovance Biotherapeutics, Inc.’s net profit fell -14.99% since last year same period to $-111.66Mn in the Q2 2025. On a quarterly growth basis, Iovance Biotherapeutics, Inc. has generated 3.88% jump in its net profits since last 3-months.

Iovance Biotherapeutics, Inc.’s net profit margin jumped 40.34% since last year same period to -186.25% in the Q2 2025. On a quarterly growth basis, Iovance Biotherapeutics, Inc. has generated 20.92% jump in its net profit margins since last 3-months.

Iovance Biotherapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.26 - a 6.54% jump from last quarter’s estimates.

Iovance Biotherapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.26.

Iovance Biotherapeutics, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Iovance Biotherapeutics, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.